DUBLIN--(BUSINESS WIRE)--The "Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myasthenia Gravis (MG) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Myasthenia Gravis Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Myasthenia Gravis Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Myasthenia Gravis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
-
Market Drivers and Barriers
Key Topics Covered:
1. Key Insights
2. Myasthenia Gravis Market Overview at a Glance
3. Market Share (%) Distribution of MG in 2017
4. Market Share (%) Distribution of MG in 2027
5. Disease Overview: Myasthenia Gravis
6. Epidemiology and Patient Population
7. Current Treatment Practices
8. Unmet Needs
9. Marketed drugs
10. Emerging Therapies
11. Myasthenia Gravis: 7 Major Market Analysis
12. Market Outlook by Country
13. Market Drivers
14. Market Barriers
15. Appendix
Companies Mentioned
- Alexion Pharmaceuticals
- Valent Pharmaceuticals
- Astellas Pharma
- Mitsubishi Tanabe Pharma
- Catalyst Pharmaceuticals
- CSL Behring
- Grifols Therapeutics,
- UCB Pharma
- Novartis
- Argenx
- Ra Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bnwf75/myasthenia_gravis?w=4
